SPARC.NS Stock Analysis
SP
Uncovered
Sun Pharma Advanced Research Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 407 full-time employees. The company went IPO on 2007-07-18. The firm is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The firm develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. The company has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. The company has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.